Nanostring claims: “RNA-Seq is not well suited for diagnostic use”

Earlier this week we learned that Nanostring Technologies of Seattle would be launching a $55M follow-on offering to its IPO last summer.  The company said net proceeds will go toward further commercialization of NanoString’s Prosigna Breast Cancer Prognostic Gene Signature Assay, including the creation of a dedicated oncology sales force and expansion of the clinical utility of the test, as well as development of additional diagnostic products.  In the prospectus filed today, the company states that although “RNA-Seq is replacing microarrays as the platform of choice for genome-wide expression analysis in research… RNA-Seq is not well suited for diagnostic use in most clinical laboratories due to its complexity, computational intensity, limited throughput and need for expert technicians. In addition, it is challenging to perform RNA-Seq analyses with small amounts of tissue, especially FFPE samples, which is a limiting factor in large scale studies and many clinical applications.”

What do you think?

Check out our latest poll and cast your vote.